Darolutamide and Survival in mHSPCIr al contenidoOncologíaDarolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer Matthew R. Smith, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142.Related ContentDarolutamide + ADT + Docetaxel in mHSPC by SubgroupsCPHSmInforme SEOM de evaluación de darolutamida en CPRCnmCPRCnmTreatment of nmCRPC: comorbidities and DDIsCPRCnm